Key facts
- · Type: New offering first sale 2025-10-28 · Amount sold: $13.50M · Total offering: $13.50M · SEC filing
- · Type: New offering first sale 2025-04-21 · Amount sold: $62.64M · Total offering: $62.64M · SEC filing
- · Type: New offering first sale 2025-02-03 · Amount sold: $10M · Total offering: $10M · SEC filing
- · Type: New offering first sale 2025-01-19 · Amount sold: $20.75M · Total offering: $20.75M · SEC filing
- · Type: New offering first sale 2022-08-09 · Amount sold: $12.87M · Total offering: $12.87M · SEC filing
Is CoRegen, Inc. a real, registered company?
CoRegen, Inc. is a registered filer with the SEC (CIK 2012886) and has filed since 2024-02-22. 6 filings are on record, the latest on 2026-02-26.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
How much has CoRegen, Inc. raised?
Its new offerings report $134.26M sold across 6 offerings, as its own filings state.
Run the free check on CoRegen, Inc. →
HOUSTON, TEXAS
2022
Biotechnology
6
$134.26M
Every filing
| Filed | Type | Amount sold | Total offering | Records |
|---|---|---|---|---|
| 2026-02-26 | New offering first sale 2025-10-28 | $13.50M | $13.50M | details · SEC filing |
| 2025-05-22 | New offering first sale 2025-04-21 | $62.64M | $62.64M | SEC filing |
| 2025-02-28 | New offering first sale 2025-02-03 | $10M | $10M | SEC filing |
| 2025-02-28 | New offering first sale 2025-01-19 | $20.75M | $20.75M | SEC filing |
| 2024-03-08 | New offering first sale 2022-08-09 | $12.87M | $12.87M | SEC filing |
| 2024-02-22 | New offering first sale 2024-02-08 | $14.50M | — | SEC filing |
Keep reading
More on CoRegen, Inc. and the records around it.
CoRegen, Inc. elsewhere on the record
- Form D filing Feb 2026
- Form D filing May 2025
Watch CoRegen, Inc.
Get an email when CoRegen, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
What do you want to do with CoRegen, Inc.?
Who to contact
- Steve Gorlin — President and Vice Chairman of the Board
- Sonal Gupta — Executive Officer
- Sonja Nelson — Chief Financial Officer and Secretary
- Bert O'Malley — Director
- Edward Benz, Jr. — Director
- Suneet Varma — Director
- Lee Fleisher — Director
- William Haseltine, PhD. — Director
- Jonathan Simons — Director
- Peter Gelinas — Executive Officer
- Round: Form D filed 2026-02-26
- Amount sold: $13.50M
- Industry: Biotechnology
- Founded: 2022
- Based: HOUSTON, TEXAS
People listed
- Steve Gorlin — President and Vice Chairman of the Board
- Sonal Gupta — Executive Officer
- Sonja Nelson — Chief Financial Officer and Secretary
- Bert O'Malley — Director
- Edward Benz, Jr. — Director
- Suneet Varma — Director
- Lee Fleisher — Director
- William Haseltine, PhD. — Director
- Jonathan Simons — Director
- Peter Gelinas — Executive Officer
- Filing: Form D filed 2026-02-26
- Amount sold: $13.50M
- Industry group: Biotechnology
- Year formed: 2022
- Based: HOUSTON, TEXAS
- Entity type: Corporation
We'll show it in your MentionFox inbox when CoRegen, Inc. raises, hires or launches. No email unless you switch it on.
Watch CoRegen, Inc. →Want the whole picture on CoRegen, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on CoRegen, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on CoRegen, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
How the total is counted: the amount sold on each new offering, added together. Amendments are left out, because an amendment restates an offering already counted. A filing whose figures have not been read yet shows a dash and adds nothing.
Every figure here is read from CoRegen, Inc.'s own filings with the SEC. The people those filings name are on the team page.